SCHEMBL23329191

SCHEMBL23329191

CSc1ccc(-n2nncc2C)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.56
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
ALDH1A1 P00352 3/20 0.50
MAPT P10636 2/20 0.50
HPGD P15428 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
FLT3 P36888 3/20 0.39
LMNA P02545 3/20 0.38
GAA P10253 1/20 0.38
NPSR1 Q6W5P4 1/20 0.35
PTGS1 P23219 3/20 0.35
PTGS2 P35354 3/20 0.35
KDM4E B2RXH2 1/20 0.33
HSD11B1 P28845 2/20 0.33
HTT P42858 1/20 0.33
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3760260 0.77 TSHR (0.59) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL14788450 0.77 TSHR (0.59) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL1500290 0.76 TSHR (0.58) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL23328981 0.74 TSHR (0.56) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL28236734 0.74 TSHR (0.56) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL18865728 0.73 TSHR (0.54) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL24469923 0.73 TSHR (0.58) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL18865730 0.73 TSHR (0.54) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL24185357 0.69 TSHR (0.50) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL24952857 0.66 TSHR (0.50) TSHRMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO TSHR 2776/4885MEN1 4787/4885KMT2A 4246/4885
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS UGDH, PGD, PNPO TSHR 2776/4885MEN1 4787/4885KMT2A 4246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.